A Joint Statement from the European Association of Urology Renal Cell Cancer Guidelines Panel and the International Kidney Cancer Coalition: The Rejection of Ipilimumab and Nivolumab for Renal Cancer by the Committee for Medicinal Products for Human Use Does not Change Evidence-based Guideline Recommendations
Publication date
2018-12
Authors
Bex, Axel
Albiges, Laurence
Staehler, Michael
Bensalah, Karim
Giles, R
Dabestani, Saeed
Hofmann, Fabian
Hora, Milan
Kuczyk, Markus A
Lam, Thomas B
Editors
Advisors
Supervisors
Document Type
Article
Metadata
Show full item recordCollections
License
taverne
Abstract
Keywords
Letter, Kidney Neoplasms/drug therapy, Nephrology/standards, Ipilimumab/adverse effects, Humans, Nivolumab/adverse effects, Treatment Outcome, Drug Approval, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Patient Selection, Evidence-Based Medicine/standards, Clinical Decision-Making, Carcinoma, Renal Cell/drug therapy, Urology/standards, Antineoplastic Agents, Immunological/adverse effects, Taverne, Urology, Letter, Practice Guideline
Citation
Bex, A, Albiges, L, Staehler, M, Bensalah, K, Giles, R H, Dabestani, S, Hofmann, F, Hora, M, Kuczyk, M A, Lam, T B, Marconi, L, Merseburger, A S, Fernández-Pello, S, Tahbaz, R, Abu-Ghanem, Y, Volpe, A, Ljungberg, B, Escudier, B & Powles, T 2018, 'A Joint Statement from the European Association of Urology Renal Cell Cancer Guidelines Panel and the International Kidney Cancer Coalition : The Rejection of Ipilimumab and Nivolumab for Renal Cancer by the Committee for Medicinal Products for Human Use Does not Change Evidence-based Guideline Recommendations', European Urology, vol. 74, no. 6, pp. 849-851. https://doi.org/10.1016/j.eururo.2018.08.029